<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04110288</url>
  </required_header>
  <id_info>
    <org_study_id>20193123</org_study_id>
    <secondary_id>U01FD004963</secondary_id>
    <nct_id>NCT04110288</nct_id>
  </id_info>
  <brief_title>VQI DELTA Paclitaxel Device Safety Analysis</brief_title>
  <acronym>VQI-PTX</acronym>
  <official_title>Vascular Quality Initiative (VQI) - Data Extraction and Longitudinal Trend Analysis (DELTA) Paclitaxel Device Safety Analysis - Phase I Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lahey Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Society for Vascular Surgery Patient Safety Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lahey Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The VQI-DELTA Paclitaxel Device Safety Analysis seeks to assess the comparative safety of
      paclitaxel coated balloons and stents in the treatment of peripheral artery disease (PAD)
      through analysis of the VQI Peripheral Vascular Intervention (PVI) registry module using the
      DELTA system.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The VQI-DELTA Paclitaxel Device Safety Analysis seeks to assess the comparative safety of
      paclitaxel coated balloons and stents in the treatment of PAD through analysis of the
      Vascular Quality Initiative (VQI) Peripheral Vascular Intervention (PVI) registry module
      using the DELTA system.

      The objective of the VQI - DELTA Paclitaxel Phase I Study is to evaluate the relative safety
      of Paclitaxel used as an antiproliferative agent in the treatment of symptomatic PAD. The
      study will analyze Paclitaxel Drug Coated Balloons (DCB) and Paclitaxel Drug Eluting Stents
      (DES), both together and as unique exposures using propensity score matched survival
      analysis. If a mortality signal is detected, factors associated with late mortality will be
      further explored. Phase I is the retrospective component of the planned study, evaluating the
      2-year survival of patients treated with a paclitaxel containing/eluting device to matched
      patients treated with non-paclitaxel devices for symptomatic PAD.

      All proposed analyses will be performed using DELTA v3.x, which has the capability to
      prospectively monitor clinical data repositories for safety signals, and is designed to
      support risk-adjusted prospective safety surveillance analyses of complex clinical datasets.

      Three principle analyses are planned:

        1. Paclitaxel DCB (including the Bard Lutonix, Medtronic In.Pact and Philips Spectranetics
           Stellarex DCB's) as compared with propensity matched patients treated with plain
           balloons.

        2. Paclitaxel delivering DES (including the Cook Zilver PTX and Boston Scientific Eluvia
           DES) as compared with propensity matched cases using bare metal stents (BMS).

        3. Patients treated with either Paclitaxel DCB or Paclitaxel DES compared with propensity
           matched controls (with DCB patients matched to patients treated with plain balloons, and
           DES patients matched to patients treated with BMS).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Actual">August 30, 2019</completion_date>
  <primary_completion_date type="Actual">August 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Survival from Death - 2 years</measure>
    <time_frame>2 years post intervention</time_frame>
    <description>Freedom from death of any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival from Death- 1 year</measure>
    <time_frame>1 year post intervention</time_frame>
    <description>Freedom from death of any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival from Limb Retreatment at 1-year</measure>
    <time_frame>1 year post intervention</time_frame>
    <description>Retreatment of the target limb or major amputation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Successful Ambulation at 1-year</measure>
    <time_frame>1 year post intervention</time_frame>
    <description>Successful ambulation</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">194163</enrollment>
  <condition>Peripheral Vascular Disease</condition>
  <arm_group>
    <arm_group_label>Uncoated Balloon Treatment</arm_group_label>
    <description>Patients treated for PAD with balloon angioplasty, without use of stent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bare Metal Stent Treatment</arm_group_label>
    <description>Patients treated for PAD with implantation of bare metal stent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paclitaxel Coated Balloon</arm_group_label>
    <description>Patients treated for PAD with drug coated balloon angioplasty, without use of stent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paclitaxel Eluting Stent</arm_group_label>
    <description>Patients treated for PAD with implantation of Paclitaxel DES.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel to treat peripheral arterial disease</description>
    <arm_group_label>Paclitaxel Coated Balloon</arm_group_label>
    <arm_group_label>Paclitaxel Eluting Stent</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Non-drug coated Device Treatment</intervention_name>
    <arm_group_label>Bare Metal Stent Treatment</arm_group_label>
    <arm_group_label>Uncoated Balloon Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients, age 18 or older, who underwent endovascular interventional treatment of the
        femoral or popliteal arteries for symptomatic PAD between 1/1/17 through 8/30/19 will be
        candidates for inclusion in the analyses.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients who underwent endovascular interventional treatment of the femoral or
             popliteal arteries for symptomatic Peripheral Artery Disease.

        Exclusion Criteria:

          -  In an effort to focus this safety evaluation on those patients being treated in
             accordance with accepted 'best practice' endovascular intervention strategies and
             'on-label' use of devices, patients will be excluded from either exposure cases or
             controls if they received a balloon expandable stent or a balloon expandable stent
             graft in the treatment of femoral or popliteal disease. Balloon expandable stents were
             excluded because these stents have historically shown inferior patency and current
             best practice favors placement of self-expanding nitinol stents which were engineered
             for the femoral popliteal segment and tested in multiple trials for this indication
             12-14.

        Additionally, patients will be excluded (as either potential cases or controls) if their
        index procedure was performed for acute limb ischemia due to the different etiologies
        (embolism, in-situ thrombosis) as compared with chronic conditions as they have different
        treatment paradigms and higher major amputation and mortality rates.

        In addition, patients with prior angioplasty or stenting of the superficial femoral artery
        (SFA)-popliteal segment will be excluded in order to avoid the possibility of improperly
        assigning paclitaxel exposure to the control group.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederic S Resnic, MD MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lahey Hospital &amp; Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel Bertges, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Society for Vascuar Surgery Patient Safety Organization</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jens Eldrup-Jorgensen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Society for Vascuar Surgery Patient Safety Organization</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lahey Clinic, Inc.</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Katsanos K, Spiliopoulos S, Kitrou P, Krokidis M, Karnabatidis D. Risk of Death Following Application of Paclitaxel-Coated Balloons and Stents in the Femoropopliteal Artery of the Leg: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc. 2018 Dec 18;7(24):e011245. doi: 10.1161/JAHA.118.011245.</citation>
    <PMID>30561254</PMID>
  </reference>
  <reference>
    <citation>Resnic FS, Majithia A, Marinac-Dabic D, Robbins S, Ssemaganda H, Hewitt K, Ponirakis A, Loyo-Berrios N, Moussa I, Drozda J, Normand SL, Matheny ME. Registry-Based Prospective, Active Surveillance of Medical-Device Safety. N Engl J Med. 2017 Feb 9;376(6):526-535. doi: 10.1056/NEJMoa1516333. Epub 2017 Jan 25.</citation>
    <PMID>28121489</PMID>
  </reference>
  <reference>
    <citation>Kumar A, Matheny ME, Ho KK, Yeh RW, Piemonte TC, Waldman H, Shah PB, Cope R, Normand SL, Donnelly S, Robbins S, Resnic FS. The data extraction and longitudinal trend analysis network study of distributed automated postmarket cardiovascular device safety surveillance. Circ Cardiovasc Qual Outcomes. 2015 Jan;8(1):38-46. doi: 10.1161/CIRCOUTCOMES.114.001123. Epub 2014 Dec 9.</citation>
    <PMID>25491915</PMID>
  </reference>
  <reference>
    <citation>Resnic FS, Gross TP, Marinac-Dabic D, Loyo-Berrios N, Donnelly S, Normand SL, Matheny ME. Automated surveillance to detect postprocedure safety signals of approved cardiovascular devices. JAMA. 2010 Nov 10;304(18):2019-27. doi: 10.1001/jama.2010.1633.</citation>
    <PMID>21063011</PMID>
  </reference>
  <reference>
    <citation>Schillinger M, Minar E. Past, present and future of femoropopliteal stenting. J Endovasc Ther. 2009 Feb;16 Suppl 1:I147-52. doi: 10.1583/1545-1550-16.16.I-147. Review.</citation>
    <PMID>19317587</PMID>
  </reference>
  <reference>
    <citation>Dick P, Wallner H, Sabeti S, Loewe C, Mlekusch W, Lammer J, Koppensteiner R, Minar E, Schillinger M. Balloon angioplasty versus stenting with nitinol stents in intermediate length superficial femoral artery lesions. Catheter Cardiovasc Interv. 2009 Dec 1;74(7):1090-5. doi: 10.1002/ccd.22128.</citation>
    <PMID>19859954</PMID>
  </reference>
  <reference>
    <citation>Chowdhury MM, McLain AD, Twine CP. Angioplasty versus bare metal stenting for superficial femoral artery lesions. Cochrane Database Syst Rev. 2014 Jun 24;(6):CD006767. doi: 10.1002/14651858.CD006767.pub3. Review.</citation>
    <PMID>24959692</PMID>
  </reference>
  <reference>
    <citation>Eliason JL, Wainess RM, Proctor MC, Dimick JB, Cowan JA Jr, Upchurch GR Jr, Stanley JC, Henke PK. A national and single institutional experience in the contemporary treatment of acute lower extremity ischemia. Ann Surg. 2003 Sep;238(3):382-9; discussion 389-90.</citation>
    <PMID>14501504</PMID>
  </reference>
  <reference>
    <citation>Earnshaw JJ, Whitman B, Foy C. National Audit of Thrombolysis for Acute Leg Ischemia (NATALI): clinical factors associated with early outcome. J Vasc Surg. 2004 May;39(5):1018-25.</citation>
    <PMID>15111854</PMID>
  </reference>
  <reference>
    <citation>Howard DP, Banerjee A, Fairhead JF, Hands L, Silver LE, Rothwell PM; Oxford Vascular Study. Population-Based Study of Incidence, Risk Factors, Outcome, and Prognosis of Ischemic Peripheral Arterial Events: Implications for Prevention. Circulation. 2015 Nov 10;132(19):1805-15. doi: 10.1161/CIRCULATIONAHA.115.016424. Epub 2015 Sep 8. Erratum in: Circulation. 2015 Nov 10;132(19):e234.</citation>
    <PMID>26350058</PMID>
  </reference>
  <reference>
    <citation>Baril DT, Ghosh K, Rosen AB. Trends in the incidence, treatment, and outcomes of acute lower extremity ischemia in the United States Medicare population. J Vasc Surg. 2014 Sep;60(3):669-77.e2. doi: 10.1016/j.jvs.2014.03.244. Epub 2014 Apr 24.</citation>
    <PMID>24768362</PMID>
  </reference>
  <reference>
    <citation>Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, Fleisher LA, Fowkes FGR, Hamburg NM, Kinlay S, Lookstein R, Misra S, Mureebe L, Olin JW, Patel RAG, Regensteiner JG, Schanzer A, Shishehbor MH, Stewart KJ, Treat-Jacobson D, Walsh ME. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017 Mar 21;69(11):1465-1508. doi: 10.1016/j.jacc.2016.11.008. Epub 2016 Nov 13. Review. Erratum in: J Am Coll Cardiol. 2017 Mar 21;69(11):1520.</citation>
    <PMID>27851991</PMID>
  </reference>
  <reference>
    <citation>Hsieh FY, Lavori PW, Cohen HJ, Feussner JR. An overview of variance inflation factors for sample-size calculation. Eval Health Prof. 2003 Sep;26(3):239-57. Review.</citation>
    <PMID>12971199</PMID>
  </reference>
  <reference>
    <citation>Cepeda MS, Boston R, Farrar JT, Strom BL. Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders. Am J Epidemiol. 2003 Aug 1;158(3):280-7.</citation>
    <PMID>12882951</PMID>
  </reference>
  <reference>
    <citation>Vidi VD, Matheny ME, Resnic FS. Post-marketing device safety surveillance. Contemp Clin Trials. 2011 May;32(3):307-8. doi: 10.1016/j.cct.2011.02.002. Epub 2011 Feb 28.</citation>
    <PMID>21371573</PMID>
  </reference>
  <reference>
    <citation>Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011 Mar-Apr;10(2):150-61. doi: 10.1002/pst.433.</citation>
    <PMID>20925139</PMID>
  </reference>
  <reference>
    <citation>Oakes D, Feng C. Combining stratified and unstratified log-rank tests in paired survival data. Stat Med. 2010 Jul 20;29(16):1735-45. doi: 10.1002/sim.3921.</citation>
    <PMID>20572124</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>September 27, 2019</study_first_submitted>
  <study_first_submitted_qc>September 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2019</study_first_posted>
  <last_update_submitted>February 26, 2020</last_update_submitted>
  <last_update_submitted_qc>February 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lahey Clinic</investigator_affiliation>
    <investigator_full_name>Frederic S. Resnic</investigator_full_name>
    <investigator_title>Chair - Division of Cardiovascular Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 27, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/88/NCT04110288/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

